Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03859934
Other study ID # 2019-000213-37
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 26, 2019
Est. completion date August 18, 2021

Study information

Verified date August 2021
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances such as insomnia or frequent awakenings are strong risk factors for T2DM with several studies indicating a central role of melatonin. Additionally, a certain single nucleotide polymorphism in the melatonin receptor gene, MTNR1B rs10830963, with an allele frequency of 30 %, is associated with increased fasting plasma glucose and T2DM. Due to treatment of, among other things, insomnia, the use of melatonin is increasing rapidly in Denmark with a 100-fold increase from 2007-2012 in children and adolescents. No previous studies have thoroughly assessed changes in glucose and fatty acid metabolism after 3 months of melatonin treatment in patients with T2DM.


Description:

Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances such as insomnia or frequent awakenings are strong risk factors for T2DM with several studies indicating a central role of melatonin. Additionally, a certain single nucleotide polymorphism in the melatonin receptor gene, MTNR1B rs10830963, with an allele frequency of 30 %, is associated with increased fasting plasma glucose and T2DM. Due to treatment of, among other things, insomnia, the use of melatonin is increasing rapidly in Denmark with a 100-fold increase from 2007-2012 in children and adolescents. No previous studies have thoroughly assessed changes in glucose and fatty acid metabolism after 3 months of melatonin treatment in patients with T2DM. Main research questions: 1. Does chronic melatonin treatment change insulin secretion in T2DM patients? 2. Does chronic melatonin treatment change insulin sensitivity in T2DM patients? 3. Does the MTNR1B rs10830963 risk allele alter the insulin secretion and insulin sensitivity compared with carries of the normal variant after chronic melatonin treatment? 4. Does chronic melatonin treatment change insulin signalling in muscle - and adipose tissue? Design: A randomized, double-blinded, placebo controlled, crossover study, including 18 participants with T2DM. We aim to recruit 9 homozygous carriers of the normal allele and 9 hetero - or homozygous for the risk allele. Participants will be examined on two occasions, 1) after 3 months of daily melatonin treatment before bedtime (10 mg), and 2) after 3 months of daily placebo treatment before bedtime. On the study days, participants will initially undergo a basal period with glucose - and palmitate tracer infusions to assess endogenous glucose production and free fatty acid production. Afterwards a Botnia clamp, which combines an intravenous glucose tolerance test and a hyperinsulinemic euglycemic clamp, will be performed to assess β-cell function and insulin sensitivity. On both study days muscle - and fat biopsies will be performed under both basal and hyperinsulinemic euglycemic conditions. Perspectives: It is highly relevant to evaluate the chronic effects of melatonin on glucose - and fat metabolism given the increase in melatonin consumption. Furthermore, the study may open for new treatment options of T2DM if beneficial effects of oral melatonin are detected.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date August 18, 2021
Est. primary completion date May 3, 2021
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Male sex - Caucasian race - Type 2 Diabetes Mellitus (T2DM) - T2DM duration of maximum 20 years - Age 40-70 years - BMI between 25-35 kg/m2 at T2DM debut - Written consent prior to study participation Exclusion Criteria: - > 3 daily antihypertensive drugs - Blood pressure > 160/100 mmHg - Insulin treatment - > 3 daily oral antidiabetic drugs - > 1 lipid lowering drug - HbA1c > 65 - Heart failure (New York Heart Association Class III or IV), liver disease (alanine aminotransferase (ALAT) > twice the upper limit of normal serum concentration), plasma creatinine > 130 µmol/L and/or albuminuria, goiter, active cancer, acute or chronic pancreatitis - Treatment with antidiabetic medicine that cannot be paused on study days (or for a week if the participants is treated with longtime-acting GLP-1 analogs) - Shift work within the last year - Travel across >4 time zones planned within the next 6 months - Use of melatonin on a regular basis within the last year - Severe illness - > 14 units of alcohol/week - Previous diagnosis of a sleep disorder - Present or earlier alcohol or drug abuse - Unable to give informed consent - Allergy towards melatonin - Daily consumption of benzodiazepines, fluvoxamine, amiodarone, efavirenz, fluoroquinolones, rifampicin, and carbamazepine due to interactions with the pharmacokinetics of melatonin. - Severe sleep apnea (>30 respiration breaks/hour over 10 seconds) - Medical treated depression or anxiety disorders within the last 3 years - Daily consumption of selective serotonin reuptake inhibitors or tricyclic antidepressants

Study Design


Intervention

Drug:
Melatonin
Melatonin treatment
Placebo Oral Tablet
Placebo treatment

Locations

Country Name City State
Denmark Medical Research Laboratory Aarhus

Sponsors (2)

Lead Sponsor Collaborator
University of Aarhus University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of insulin sensitivity Insulin sensitivity is assessed by a hyperinsulinemic euglycemic clamp, unit: mg/kg/min (mg of glucose to maintain euglycemia per kilogram of weight per minuts) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment and compared afterwards with a paired T-tes
Primary Change of insulin secretion change Insulin secretion is assessed by an intravenous glucose tolerance test, unit: pmol/L (insulin) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Primary MTNR1a rs10830963 influence on change in insulin sensitivity and insulin secretion MTNR1a rs10830963 genotype influence on insulin sensitivity and insulin secretion (see outcome 1 + 2) The outcome will be measured after 3 months of placebo treatment and again after 3 months of melatonin treatment
Primary Change of insulin signalling Insulin signalling in muscle and adipose tissue assessed by western blot The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of ambulatory blood pressure Ambulatory blood pressure assessed with Mobil-O-graph, I.E.M., Stolberg, Germany (Unit: mmHg) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of arterial stiffness Arterial stiffness assessed with Mobil-O-graph, I.E.M., Stolberg, Germany (unit: m/s) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of gut microbiome Feces analysis of microbial mRNA The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of sleep evaluation 1 Pittsburg Sleep Quality Index Questionnaire (Points on a scale: range 0-57) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of sleep evaluation 2 Epworth Sleepiness Scale Questionnaire (Points on a scale: range 0-24) After 3 months treatmentThe outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of psychological health 1 Major Depression Inventory Questionnaires (points on a scale: range 0-65) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of psychological health 2 World Health Organization 5 Questionnaires (points on a scale: range 0-25) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Hormonal changes Ghrelin, HbA1c, GLP-1, GLP-2, GIP, free fatty acids (FFA), leptin, cytokines, adiponectin, growth hormone, cortisol, hsCRP, CD163, MBL, IGF-1 and proinsulin measured by ELISA, RIA, or routine biochemical analysis. Unit: pmol/L The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of glucose and palmitate kinetics Tracer technique with infusion of radioactive labeled glucose and palmitate for determination of rate of appereance. Unit: mikromol/min The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of regional glucose and palmitate uptake Forearm model with arteriovenous differences of glucose and palmitate (Arterial glucose minus venous glucose = forearm uptake (unit mmol/l). The same applies for palmitate The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of DEXA-scans Evaluation of body composition and bone mineral density by DEXA-scan The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of assessment of respiratory quotient (RQ) Assessment of respiratory quotient (RQ) with indirect calorimetry (unit: VCO2/VO2) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
Secondary Change of assessment of resting energy expenditure (REE) Assessment of resting energy expenditure (REE) with indirect calorimetry (Unit J/s) The outcome will be measured after 3 months of placebo treatment and after 3 months of melatonin treatment
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
Completed NCT02226003 - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Phase 3